258 related articles for article (PubMed ID: 9425392)
1. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
2. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
4. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
6. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
7. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
Franklyn J; Betteridge J; Holder R; Daykin J; Lilley J; Sheppard M
Clin Endocrinol (Oxf); 1994 Oct; 41(4):425-32. PubMed ID: 7955453
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.
Garton M; Reid I; Loveridge N; Robins S; Murchison L; Beckett G; Reid D
Clin Endocrinol (Oxf); 1994 Dec; 41(6):747-55. PubMed ID: 7889610
[TBL] [Abstract][Full Text] [Related]
10. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
11. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women.
Baqi L; Payer J; Killinger Z; Susienkova K; Jackuliak P; Cierny D; Langer P
Endocr Regul; 2010 Jan; 44(1):9-15. PubMed ID: 20151763
[TBL] [Abstract][Full Text] [Related]
12. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
13. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
[TBL] [Abstract][Full Text] [Related]
14. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
15. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
16. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density and metabolism in children treated with L-thyroxine.
Tümer L; Hasanoğlu A; Cinaz P; Bideci A
J Pediatr Endocrinol Metab; 1999; 12(4):519-23. PubMed ID: 10417967
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation.
Gyulai L; Bauer M; Garcia-Espana F; Hierholzer J; Baumgartner A; Berghöfer A; Whybrow PC
J Affect Disord; 2001 Oct; 66(2-3):185-91. PubMed ID: 11578671
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease.
Jódar E; Martínez-Díaz-Guerra G; Azriel S; Hawkins F
Calcif Tissue Int; 2001 Aug; 69(2):84-7. PubMed ID: 11683428
[TBL] [Abstract][Full Text] [Related]
20. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
